Wall Street brokerages expect Retrophin, Inc. (NASDAQ:RTRX) to report $40.82 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Retrophin’s earnings. The lowest sales estimate is $39.14 million and the highest is $42.50 million. Retrophin reported sales of $33.95 million during the same quarter last year, which indicates a positive year over year growth rate of 20.2%. The business is expected to announce its next earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that Retrophin will report full year sales of $40.82 million for the current fiscal year, with estimates ranging from $152.69 million to $154.80 million. For the next fiscal year, analysts forecast that the business will report sales of $184.40 million per share, with estimates ranging from $184.19 million to $184.60 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover Retrophin.
Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). The business had revenue of $38.80 million for the quarter, compared to analysts’ expectations of $37.36 million. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The business’s revenue for the quarter was up 16.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.07 earnings per share.
A number of research firms have recently weighed in on RTRX. BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. ValuEngine cut Retrophin from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $44.00 target price on shares of Retrophin in a research note on Friday, October 6th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $36.00.
COPYRIGHT VIOLATION WARNING: This story was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.thestockobserver.com/2017/10/12/retrophin-inc-rtrx-expected-to-announce-quarterly-sales-of-40-82-million.html.
Retrophin (RTRX) traded up 0.021% during trading on Monday, hitting $24.265. The stock had a trading volume of 226,733 shares. The stock’s 50-day moving average is $24.05 and its 200 day moving average is $20.29. The firm’s market cap is $931.41 million. Retrophin has a one year low of $15.55 and a one year high of $25.44.
In related news, COO Neil F. Mcfarlane sold 1,378 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the transaction, the chief operating officer now directly owns 13,622 shares in the company, valued at $306,495. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.41% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company increased its stake in Retrophin by 6.1% in the second quarter. The Manufacturers Life Insurance Company now owns 30,077 shares of the biopharmaceutical company’s stock valued at $583,000 after purchasing an additional 1,733 shares during the last quarter. Macquarie Group Ltd. increased its stake in Retrophin by 17.0% in the second quarter. Macquarie Group Ltd. now owns 1,188,819 shares of the biopharmaceutical company’s stock valued at $23,051,000 after purchasing an additional 172,389 shares during the last quarter. PDT Partners LLC increased its stake in Retrophin by 323.9% in the second quarter. PDT Partners LLC now owns 151,159 shares of the biopharmaceutical company’s stock valued at $2,931,000 after purchasing an additional 115,503 shares during the last quarter. Voya Investment Management LLC increased its stake in Retrophin by 11.8% in the second quarter. Voya Investment Management LLC now owns 17,905 shares of the biopharmaceutical company’s stock valued at $347,000 after purchasing an additional 1,891 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Retrophin by 49.0% in the second quarter. Dimensional Fund Advisors LP now owns 825,253 shares of the biopharmaceutical company’s stock valued at $16,002,000 after purchasing an additional 271,551 shares during the last quarter.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.